Biktarvy

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

HIV InfectionImmunodeficiencyCoronary Atherosclerosis

326 competitors in HIV Infection

#DrugCompanyPhaseTrials

1

Leukine

Sanofi

Phase 3

22

Intron a

Merck & Co.

Phase 3

13

Sunlenca

Gilead

Phase 3

14

Praluent

Regeneron

Phase 3

15

Betaseron

Bayer

Phase 3

—6

PEG-Intron

Merck & Co.

Phase 3

—7

Megace

Bristol-Myers Squibb

Phase 3

—8

Isentress

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

39

Proleukin

IIovance Biotherapeutics, Inc.

Phase 3

210

Foscavir

NNational Institute of Allergy and Infectious Diseases (NIAID)

Phase 3

1Show 36 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

13 more indications

Treatment1 trial

The Late Presenter Treatment Optimisation Study

Completed·NNEAT ID Foundation·Phase 3·NCT03696160·447 enrolled

Weight Gain1 trial

Effect of Biktarvy & Symtuza on microRNAs in HIV and Correlation With Weight Gain

Unknown status·—·Phase 4·NCT05463783·30 enrolled

HIV infection1 trial

Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat'

Completed·CChelsea and Westminster NHS Foundation Trust·Phase 3·NCT04653194·36 enrolled

Diagnosis1 trial

A Test and Treat Strategy in New HIV Diagnosis.

Completed·JJudit Pich Martínez·Phase 3·NCT04416906·100 enrolled

Immunodeficiency1 trial

A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed

Completed·GSK·Phase 3·NCT04542070·687 enrolled

Tenofovir1 trial

Safety, Tolerability, and Efficacy of a Dose Reduction Strategy Based on Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-infected Adults

Completed·FFundacion Clinic per a la Recerca Biomédica·Phase 4·NCT05602506·40 enrolled

Acceptability1 trial

Efficacy, Tolerability and Acceptability of Biktarvy by TPLWH

Terminated·CChelsea and Westminster NHS Foundation Trust·Phase 4·NCT04944654·1 enrolled

Insulin Sensitivity1 trial

The Effect of Biktarvy (B/F/TAF) on Whole-body Insulin Sensitivity, Lipid and Endocrine Profile in Healthy Volunteers

Completed·CChelsea and Westminster NHS Foundation Trust·Phase 1·NCT04950530·25 enrolled

Outcome1 trial

Real-Life Outcomes of TAF/FTC/BIC in HIV Patients in Colombia

Completed·SServicios de Salud IPS Suramericana S.A.S··NCT06829082·161 enrolled

Drug1 trial

Implementation of Onsite, Rapid ART Initiation Among People Who Inject Drugs Living With HIV at Syringe Services Program

Completed·UUniversity of Miami·Phase 4·NCT04650269·27 enrolled

Medication1 trial

Switch to TAF+FTC+BIC in HIV-1-infected Patients Over 65 Years Old at Risk of Polymedication

Unknown status·IInstitut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba·Phase 4·NCT04222283·27 enrolled

HIV1 trial

Effects of Biktarvy on CFR in Stable HIV Patients

Completed·—·Phase 3·NCT03656783·25 enrolled

Effectiveness1 trial

Real World Effectiveness of Bictegravir/Emtricitabine/Tenofovir Alafenamide(BIC/FTC/TAF) in PLWH in Precarity Settings in France -IMEA073

Not yet recruiting·IInstitut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba··NCT07122557·320 enrolled

Details

Drug Info

Related News